Could a common amino acid help fight colorectal cancer?
NCT ID NCT07577505
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking histidine, an amino acid supplement, can safely boost the immune system's ability to fight colorectal cancer. Twenty participants will take 2 grams of histidine daily for 9 weeks alongside their standard cancer treatment. Researchers will measure changes in immune cell activity and tumor size.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Histidine (an amino acid supplement)
- What this could lead to
- If it works, this could point toward a simple dietary supplement to help the immune system fight colorectal cancer better alongside standard treatments.
- What could go wrong
- This is a very small, early-stage study with only 20 participants and no placebo group. It only measures immune markers, not whether the cancer actually shrinks or survival improves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Punan Hospital of Pudong New District
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices